Canagliflozin FDA Approved For Type 2 Diabetes

Canagliflozin FDA Approved For Type 2 Diabetes

Canagliflozin FDA ApprovedCanagliflozin FDA approved as a new and unique treatment for type 2 diabetes.

There were nine clinical trials involving more than 10,285 patients with type 2 diabetes. The trials showed positive results with greater glycemic control in patients.

The recommended use for Canagliflozin patients includes a strict regimen of diet and exercise. The drug also outperforms similar diabetes drugs like Glimepiride (Amaryl) and Sitagliptin (Januvia).

However, the need for additional postmarketing studies is required by the FDA.

Some “Canagliflozin” Factoids:

  • Canagliflozin does not rely on patient’s insulin levels to succeed.
  • Canagliflozin is a unique inhibitor of sodium glucose co-transporter 2, as well as a potential treatment for type 2 diabetes.
  • Results from five Phase lll clinical trials, which were presented at the 72nd American Diabetes Association Annual Scientific Sessions on June 9, 2012.
  • Results in favor of Canagliflozin were positive, showing that a once daily 300 mg dose of this medication provided significantly greater reductions in A1C levels relative to comparators.
  • In January 2013 an FDA Advisory Committee recommended approval of Canagliflozin for type 2 diabetes in adults based on efficacy & safety results from the comprehensive clinical development program
  • Canagliflozin CAS# 842133-18-0 is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney
  • Canagliflozin will be marketed under the brand name INVOKANA™ by J&J

LGM Pharma provides Canagliflozin CAS# 842133-18-0 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service